Status:
UNKNOWN
Connectivity Alterations After Levetiracetam Application
Lead Sponsor:
Beijing Neurosurgical Institute
Collaborating Sponsors:
Beijing Tiantan Hospital
Conditions:
Glioma
Epilepsy
Eligibility:
All Genders
18-75 years
Brief Summary
This study aimed to analyze the connectivity alterations in brain networks of LGG patients with epilepsy who take levetiracetam at short-term preoperatively.
Detailed Description
Glioma-related epilepsy (GRE) is a very common symptom in patients with diffuse gliomas. Approximately 60% of patients with low-grade gliomas (LGGs) and 40-64% of patients with high-grade gliomas pres...
Eligibility Criteria
Inclusion
- Age ≥ 18 years;
- Histopathological diagnosis with LGG according to the 2016 World Health Organization (WHO) criteria;
- Participants received more than 6 years of school education;
- Presence of GRE, take levetiracetam less than 1 month; or do not take any medicine and receive any treatment;
- No history of biopsy, radiotherapy, or chemotherapy.
Exclusion
- Contraindications for MRI;
- Head motion greater than 3 mm in translation or 3° in rotation;
Key Trial Info
Start Date :
May 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04425798
Start Date
May 25 2022
End Date
September 30 2022
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Neurosurgical Institute and Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070